pone.0206838.g001.tif (858.45 kB)
The number of individuals screened, randomized, allocated and withdrawn from the trial and the number of samples analyzed.
figure
posted on 2018-11-29, 18:39 authored by Edna O. Viegas, Arne Kroidl, Patricia J. Munseri, Marco Missanga, Charlotta Nilsson, Nelson Tembe, Asli Bauer, Agricola Joachim, Sarah Joseph, Philipp Mann, Christof Geldmacher, Sue Fleck, Wolfgang Stöhr, Gabriella Scarlatti, Said Aboud, Muhammad Bakari, Leonard Maboko, Michael Hoelscher, Britta Wahren, Merlin L. Robb, Jonathan Weber, Sheena McCormack, Gunnel Biberfeld, Ilesh V. Jani, Eric Sandström, Eligius LyamuyaThe number of individuals screened, randomized, allocated and withdrawn from the trial and the number of samples analyzed.
History
Usage metrics
Categories
Keywords
CN 54rgpadjuvanted proteinbinding antibody responses20 volunteersResults VaccinationsGLA-AFsaline placeboIFNintradermal HIV-DNA regimenEnv-specific responsesphase II randomized factorial trial design BackgroundEPDNA-induced Gag response ratesGlucopyranosyl Lipid16 weeksHIV-DNA intradermalHIV-uninfected adultsvaccinia virus AnkaraEnv peptide poolsELISpot response rates10 8 pfu HIV-MVAHIV-MVA vaccine-specific GagGroup IIIConclusion Intradermal electroporationneutralizing antibody responsesTZM-bl assaysubtype C CN 54rgp envelope protein adjuvantedneedle-free ZetaJet deviceantibody responsessafety concerns
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC